AC Immune (NASDAQ:ACIU) Stock Price Passes Below 50 Day Moving Average – Should You Sell?

AC Immune SA (NASDAQ:ACIU) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.71 and traded as low as $2.60. AC Immune shares last traded at $2.64, with a volume of 161,167 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of AC Immune in a report on Friday, November 15th.

AC Immune Price Performance

The stock has a market cap of $261.20 million, a price-to-earnings ratio of -5.74 and a beta of 1.30. The company’s fifty day simple moving average is $2.71 and its two-hundred day simple moving average is $3.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC purchased a new position in shares of AC Immune in the 4th quarter worth approximately $118,000. Two Sigma Advisers LP bought a new position in AC Immune in the 4th quarter valued at $36,000. Cantor Fitzgerald L. P. bought a new position in AC Immune in the 4th quarter valued at $68,000. Jane Street Group LLC purchased a new stake in shares of AC Immune during the 4th quarter valued at $66,000. Finally, Northern Trust Corp bought a new stake in shares of AC Immune during the 4th quarter worth $1,088,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.